Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexigen Therapeutics IncfiledCriticalOrexigen Therapeutics Inc
Priority to CR20160217ApriorityCriticalpatent/CR20160217A/en
Publication of CR20160217ApublicationCriticalpatent/CR20160217A/en
La presente descripción se refiere a composiciones, kits, usos, sistemas y métodos para tratar el sobrepeso y la obesidad, mediante el uso de naltrexona más bupropión, con preferencia, en combinación con un programa integral de control de peso gestionado por Internet y/o por vía telefónica y, con preferencia, en sujetos que corren un riesgo mayor de sufrir resultados cardiovasculares adversos.The present description refers to compositions, kits, uses, systems and methods for treating overweight and obesity, by using naltrexone plus bupropion, preferably in combination with a comprehensive weight management program managed by the Internet and / or by telephone and, preferably, in subjects who are at a higher risk of suffering adverse cardiovascular outcomes.
CR20160217A2016-05-062016-05-06
COMPOSITION AND METHODS FOR THE TREATMENT OF OVERWEIGHT AND OBESITY
CR20160217A
(en)
METHOD OF TREATING A SUBJECT WHO IS AT RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD TO PREVENT OR DELAY THE START OF SAID EVENT, METHOD TO TREAT A SUBJECT DUE TO OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICATION